Olympus 2012 Annual Report Download - page 46

Download and view the complete annual report

Please find page 46 of the 2012 Olympus annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 105

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105

MEDICAL BUSINESS
Review of Operations > Medical Business
Consolidated Net Sales
¥349.2
billion
Consolidated Operating Income
¥68.2
billion
Fiscal 2012 Business Results and Activities
In the first half of fiscal year ended March 31, 2012, sales of mainstay
gastrointestinal endoscopes (LUCERA series) were substantially affected by the
Great East Japan Earthquake. In the second half of the year, however, product
supply was restored and sales were strong. As a result, full-year net sales and
operating income fell only 2% and 5% year-on-year, respectively.
Although the impact on business of the deferred posting of past losses was
a concern, business partners and physicians were understanding. As a result,
the impact was limited, and the business was supported by strong demand.
Consolidated net sales rose 3% and operating income rose 4% year-on-
year, excluding the impact of foreign exchange transactions. Today, the Medical
Business is achieving steady sales growth.
New Products
In our endoscopy, surgical, and endotherapy device businesses, Olympus has
made significant progress in the development of strategically important new
products that will serve as future growth drivers. In the spring of 2012, Olympus
introduced to the gastrointestinal endoscopy field the EVIS EXERA III series, a
next-generation gastrointestinal endoscope system, and Axeon, Olympus’ first
low-cost endoscope model for emerging markets.
In the surgical device field, Olympus introduced VISERA ELITE, a surgical
endoscopy video system, as well as THUNDERBEAT, the world’s first surgical
energy device capable of simultaneously delivering bipolar high-frequency and
ultrasonic energies.
Others
3.0％
Japan
23.0％
North America
34.7％
Europe
26.3％
Asia
13.0％
Share of
Net Sales
by Region Operating income (Billions of yen)
Endoscopes
Surgical and endotherapy devices
Operating margin (%)
EBITDA (%)
Net Sales Average Annual Growth Target of 10%
Average Annual Growth Target of 13%
(Billions of yen)
2011 (FY)
(FY)
2012 2013
(Plan)
2015
(Plan)
2017
(Plan)
55%
355.3
45%
55%
349.2
45%
50%
570.0
50%
52%
470.0
48%
53%
383.0
47%
Operating Income, Operating Margin, EBITDA
2011 2012 2013
(Plan)
2015
(Plan)
2017
(Plan)
20
71.7
20
68.2
28
22
126.0
21
97.0
20
27 27 27
26
75.0
Akihiro Taguchi
President
Medical Group
(Fiscal 2012 results)
44 OLYMPUS 󱚈 Annual Report 2012